Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017

This review of novel oncology drugs approved by the US Food and Drug Administration examines the use of surrogate end points for overall survival, evaluates the use of patient-reported outcomes in trials supporting approvals, and seeks to determine whether drugs initially approved without evidence o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Zettler, Marjorie, Basch, Ethan, Nabhan, Chadi
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Research Letter
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6613294/
https://ncbi.nlm.nih.gov/pubmed/31268471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1760
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky